X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Gliovac (sitoiganap/ERC 1671) is an advanced immunotherapy derived from brain tumor tissue that is surgically removed from patients with rGBM,Such tumor tissue is then processed to obtain inactivated intact cells and disrupted lysed cells from different patients.
Lead Product(s): Sitoiganap,GM-CSF,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Gliovac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
The expansion of ERC’s RTT program makes its unique immuno-oncology GBM treatment, ERC1671, available to a wider number of patients who have exhausted all other treatment options.
Lead Product(s): Sitoiganap,Sargramostim,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Gliovac
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
The MAA contains observations suggesting safety and efficacy of SITOIGANAP demonstrated from the interim data of a randomized double-blind phase II trial.
Lead Product(s): Sitoiganap,Sargramostim,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ERC1671
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
